EGFR and non-small cell lung carcinoma: Patients harboring either of these two mutations represent a classic subtype of NSCLC, with a higher response to EGFR-TKIs and even improved overall survival (OS) rates compared to patients with wild-type EGFR tumors [16,17,18].